abs150.txt	background		although	induction	studies	of	tpf	in	scchn	have	not	improved	outcomescompared	to	chemoradiotherapy	alone	phase	ii	weekly	carboplatin(cbp)	paclitaxel	and	cetuximab	(c225)	shown	promising	results	nano-albumin-paclitaxel	(nab-paclitaxel)	based	chemotherapy	has	demonstrated	ahigher	response	rate	(rr)	than	solvent-based	squamous	cellcarcinoma	the	lung	with	favorable	toxicity	materials	methods	patients	treatment	naïve	any	site	≥n2bdisease	or	that	was	unresectable	by	strict	criteria	were	eligible	weretreated	nab-paclitaxel	100	mg/m2	cbp	area	under	curve	(auc)	2	c225400	week	1	then	250	for	six	weeks	followed	standard	carechemoradiotherapy	(crt)	primary	endpoint	clinical	toinduction	therapy	as	defined	recist	version	secondary	measures	includedtoxicity	progression-free	survival	overall	quality	life	asmeasured	fact-hn	38	subjects	treated	sites	oropharynx	(opx)(25)	larynx	(3)	oral	cavity	(oc)	(9)	hypopharynx	(1)	most	common	grade	3or	4	during	acneiform	rash	(26%)	neutropenia(16%)	rr	76	3%	median	pfs	os	been	reached	(median	follow-up	of3	3	years)	they	superior	conclusions	combination	c225	is	feasible	tolerable	active	against	locally	advanced
